Alcohol and Breast Cancer Incidence and Outcome: A Minireview of Literature

Rizwan Qamar¹, Mashhood A. Syed², Jonatahn Yin Amtul R. Carmichael²*

¹Department of Histopathology, Russells Hall Hospital, Dudley, UK
²Department of General Surgery, Russells Hall Hospital, Dudley, UK
Email: *Amtul.Carmichael@dgh.nhs.uk

Received 13 May 2014; revised 23 June 2014; accepted 3 August 2014

Abstract
There is strong epidemiological evidence, based on 15 prospective studies, 10 meta-analyses, and 5 systematic reviews involving more than 2.2 million patients, that alcohol consumption is a contributing factor for the development of breast cancer. The evidence regarding the effect of alcohol consumption on breast cancer outcome needs to be gathered in order to draw firm conclusions regarding alcohol consumption after breast cancer diagnosis. In this article, we aim to review the current literature regarding recurrence and all-cause and BC cause mortality and identify postulated. We would make suggestions for future research.

Keywords
Breast Cancer, Alcohol Consumption, Recurrence, Mortality

Subject Areas: Oncology, Surgery & Surgical Specialties, Women’s Health

1. Introduction
Robust epidemiological and scientific evidence has recognised the carcinogenic effects of alcohol on the development of cancer of the oral cavity, the pharynx, the larynx, as well as the squamous cell carcinoma of the oesophagus and the liver [1]-[3]. The evidence that alcohol plays a causal role in the development of breast cancer (BC) has consolidated recently [4] [5]. The exact cause of breast cancer is unknown, and the development of breast cancer is attributable to the life time exposure of Oestrogen. The incidence of breast cancer is higher in postmenopausal obese women, those from deprived backgrounds, and is lower in premenopausal obese women. The exact mechanism by which alcohol exerts its carcinogenic effect on BC is not fully understood.

2. Alcohol Intake
According to the NHS guidelines in the UK, women should not regularly exceed more than 2 - 3 units per day

which is equivalent to 1 pint of strong lager (3 units) or 1 large glass of wine (3 units). According to the NHS guidelines the categories of alcohol consumption and risk are as following. Lower Risk—No more than 2 - 3 units (One unit equals 10ml or 8g of pure alcohol) per day on a regular basis, Increasing Risk—More than 2 - 3 units per day on a regular basis, Higher Risk—More than 35 units per week on a regular basis [56].

3. Alcohol Intake and BC Incidence

A clear dose-response relationship between alcohol consumption and the development of BC was shown in a pooled analysis of >300,000 women recruited in 6 prospective studies from North America and Europe [6]. Each 10 g increment of alcohol consumed increased the relative risk of developing BC by 9% (95% CI, 1.04 - 1.13) [6]. The dose response relationship was suggested by a linear increase in the risk of developing BC with an increasing alcohol intake of up to 60 g per day. It is estimated that consuming two or more drinks per day (equivalent to ≥30 g), increased the risk of developing BC by 40% [6]-[9]. In a recent large meta-analysis Hamajima et al. (2002) examined data from 53 studies including more than 58,000 women with invasive BC and more than 95,000 controls. The relative risk of developing BC was increased by 32% (19% - 45%, P < 0.00001) and 46% (33% - 61%, P < 0.00001) respectively, for intakes of 35 - 44 g/day and ≥45 g/day compared to non-drinkers [10]. Similarly for each additional 10 g/day of alcohol intake the relative risk was increased by 7% (5.5% - 8.7%, P < 0.00001) [10]. More recently “The Million Women Study”, a large prospective cohort study following approximately 1.3 million women from the NHSBSP (National Health Service Breast Screening Programme) has reaffirmed the association between alcohol consumption and developing breast cancer. It was shown that an increase in alcohol consumption of 10 g/day resulted in a 12% increased risk of BC (95% CI = 1.09 - 1.14, P_trend < 0.001) [2]. A dose response relationship was also suggested by Chen et al. (2011) in a prospective observational study of >100,000 women; every 10 g increment of alcohol consumed increased relative risk of developing BC by 7% [11]. This association was further consolidated by The World Cancer Research Fund (WCRF) Report in 2010; the review of evidence found that 31 out of 57 of its investigated studies showed a significantly increased risk of BC related to increased alcohol consumption [12]. In their second expert report; a meta-analysis of cohort studies showed that 10 g consumption of ethanol led to a 10% increased risk for all-age breast cancer, a 9% increased risk for premenopausal BC and a 8% increased risk for postmenopausal breast cancer; thus the (WCRF) report classified the evidence for alcohol as a cause for BC as convincing [13].

Even consumption of small amounts of alcohol has been shown to increase the risk of developing breast cancer. A review of the evidence in 2012 concluded that having 1 alcoholic drink/day (~1.5 units) increased the risk by 4% [14]. This finding was further supported by a meta-analysis by Bagnardi et al. (2013) which looked specifically at the effects of light alcohol consumption (up to 1 drink/day); 222 articles were evaluated which included ~92,000 light drinkers and 60,000 non-drinkers with cancer. Light drinking was significantly associated with the risk of developing BC (RR = 1.05; 95% CI 1.02 - 1.08) [15]. However, an association between alcohol consumption and BC is not undisputed. Zhang and Holman (2011) reported that low to moderate alcohol intake (<10 g/day) was not associated with increased risk of BC in pre- or postmenopausal women (a case-control study of 1009 breast cancer and 1009 age-matched controls in China) [16]. In fact they showed an inverse relationship with development of BC for <10 g of Ethanol consumed daily (For >0 - <5 g/day OR 0.56 (CI 0.45 - 0.69, P < 0.001), and for >5 - <10 g/day OR 0.58 (CI 0.35 - 0.98, P = 0.04). However, their data also showed a significant association between consuming ≥30 g ethanol/day and development of BC (OR 2.33 (CI 1.26 - 4.31, P < 0.01). This study supports the hypothesis that increased alcohol intake can increase the risk of developing BC.

The Proposed Mechanisms Linking Alcohol with BC Development

The exact mechanism by which alcohol may promote carcinogenesis is not fully understood. In a recent review article Brooks and Zakhari (2012) consolidated much of the known and postulated mechanisms by which alcohol is thought to contribute to the development of breast cancer. They arrived at two distinct mechanisms by which alcohol may act, firstly as a breast tumour promoter and secondly as a weak cumulative breast carcinogen [36]. It is postulated that alcohol may cause DNA damage, elevated levels of steroid hormones, and enhanced gland susceptibility [17]. Alcohol interferes with folate absorption, transport, and metabolism causing or exacerbating
Acetaldehyde, the primary metabolite of alcohol in the human body has also been implicated in carcinogenesis. The International Agency for Research into Cancer (IARC) classifies acetaldehyde associated with alcohol drinking as a Group 1 Carcinogen [3]. Experimental evidence in animals has shown the conversion of ethanol to acetaldehyde in mammary tissue to have a significant effect on the progression of tumour development [33].

Experimental evidence also suggests that alcohol may enhance the metastatic potential of BC cells over expressing ErbB2 or HER2. Amplification of HER2 is found in 20% to 30% of patients with breast cancer [34]. Xu et al. (2010) investigated the effects of ethanol on attachment of HER2 + BC cells to human plasma fibronectin; an important constituent of the extra cellular matrix, and adhesion to it constitutes a key initial step in cancer cell invasion and metastasis. They found that exposure to ethanol drastically enhanced adhesion of HER2 + BC cells to fibronectin [35].

A possible explanation for the association between alcohol and BC includes hormone dependent mechanisms mediated by sex hormone receptors [18] [21]. Many studies have been undertaken to investigate an association between alcohol intake and BC risk dependent on oestrogen receptor (ER) and progesterone receptor (PR) status (Table 1) [19] [25]. The findings have been inconsistent, probably due to incomplete information on receptor status [19] [20] [24]-[27]. A meta-analysis of seven case-control and three cohort studies assessed the association between alcohol intake and the risk of ER-/PR- defined BC found statistically significant increased risks for all ER+ (12%), all ER- (7%), ER+PR+ (11%) and ER+PR- (15%), but not ER–PR– with an increased consumption of alcohol by 10 g per day [28]. The expression and proliferation of ERs in cultured human BC cells is increased by alcohol and therefore could possibly be associated with the development of positive, but not negative ER BC cells [25] [29] [30]. Furthermore, it is thought that the use of aromatase inhibitors and other anti-oestrogen therapy could possibly counteract the effects of alcohol on the endogenous oestrogen supply [17] [25] [30].

### Table 1. Association between alcohol intake and breast cancer risk depending on ER and PR status.

<table>
<thead>
<tr>
<th>Author</th>
<th>Number of cases</th>
<th>Hormonal status of patients used</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Suzuki et al., 2005 [20]</td>
<td>1188</td>
<td>Postmenopausal</td>
<td>Alcohol consumption was associated with an increased risk for the development of ER-positive (+) tumours, irrespective of PR status. Highest intake (≥10 g of alcohol per day) vs. non-drinkers, multivariable relative risk (RR): 1.35 (95% CI: 1.02 to 1.80); P trend &lt; 0.049 for ER+PR+ tumours; and RR: 2.36 (95% CI: 1.56 to 3.56); P trend &lt; 0.001 for ER+PR– tumours. No association was observed between alcohol intake and the risk of developing ER-tumours.</td>
</tr>
<tr>
<td>L. U. Rosenberg et al., 2006 [22]</td>
<td>3345</td>
<td>Postmenopausal</td>
<td>Alcohol intake of ≥10 g/d was associated with a seemingly higher risk of ER-PR-tumours odds ratio (OR): 1.6 (95% CI: 0.9 to 2.7) than for ER+PR+ tumours, OR: 1.0 (95% CI: 0.6 to 1.6) compared with no recent alcohol intake.</td>
</tr>
<tr>
<td>M. Cotterchio et al., 2003 [23]</td>
<td>3276</td>
<td>Pre- and Postmenopausal</td>
<td>Compared with non-drinkers, heavy consumption of alcohol (&gt;3.5 alcoholic beverages/week) was associated with a non-statistically significant increased risk of ER–PR– breast cancer but was not associated with ER–PR+ breast cancer. Consuming moderate amounts of alcohol (1 - 2.5 drinks/week) was associated with an increased risk of ER–PR– tumours (not statistically significant) but was not associated with ER–PR+ tumours. The heterogeneity between these MVORs was statistically significant (P = 0.03).</td>
</tr>
<tr>
<td>S. M. Enger et al., 1999 [27]</td>
<td>1184</td>
<td>Pre- and Postmenopausal</td>
<td>Alcohol use not associated with premenopausal risk of breast cancer, regardless of hormone-receptor status. In postmenopausal women, those who consumed, on average, &gt;27 g of alcohol/day experienced an OR: 1.76 (95% CI: 1.14 to 2.71) for ER-positive/PR-positive breast cancer relative to women who reported no alcohol consumption.</td>
</tr>
<tr>
<td>M. B. Terry et al., 2006 [24]</td>
<td>1508</td>
<td>Pre- and Postmenopausal</td>
<td>Alcohol consumption of approximately one drink per day was associated with ER-positive tumours among women with a BMI &lt; 25, but not among women with a BMI of 25 or more.</td>
</tr>
<tr>
<td>S. M. Zhang et al., 2007 [25]</td>
<td>1484</td>
<td>Pre- and Postmenopausal</td>
<td>An increased risk was limited to ER and PR positive tumours; the multivariable relative risks for an increment of 10 g/day of alcohol were 1.11 (95% CI: 1.03, 1.20) for ER+PR+ tumours (804 cases), 1.00 (95% CI: 0.81, 1.24) for ER+PR– tumours (125 cases), and 0.99 (95% CI: 0.82, 1.20) for ER–PR– tumours (167 cases).</td>
</tr>
</tbody>
</table>
4. Alcohol and BC Outcome

A possible role of alcohol consumption in BC recurrence and mortality has received little research attention. There have been multiple studies investigating alcohol and mortality as the primary endpoint [29] [30] [37]-[48], but few which have specifically considered alcohol in relation to BC recurrence [30] [40] [44] [49]-[53].

We shall first consider studies investigating alcohol and overall mortality in women with BC. There are no specific studies addressing the overall mortality in breast cancer survivors in terms of alcohol consumption. However, studies by Reding [29] and Wu [54] address this question to some extent. This remains an area for future research.

4.1. Breast Cancer, Alcohol and Overall Mortality

Six out of 8 studies published between 1991 and 2008 showed no association of alcohol intake and mortality. A further 6 recent prospective studies published between 2008 and 2013 were identified, which reported decreased overall mortality associated with increased alcohol intake [42]-[47].

Barnett et al. (2008) showed a 2% reduction (95% CI, 1% to 3% \(P = 0.0045\)) in mortality per unit of alcohol consumed per week, however, after adjusting for Type 1 errors, the association was no longer significant (\(P_{adj} = 0.144\)) [42].

Reding et al. (2008) found that all levels of alcohol consumption prior to a diagnosis of BC were associated with reduced risk of death [0 to <3 drinks per week: HR = 0.7 (95% CI: 0.6 - 0.95); 3 to <7 drinks per week: RR = 0.6 (95% CI: 0.4 - 0.8); ≥7 drinks per week: RR = 0.7 (95% CI: 0.5 - 0.9)] [29].

Flatt et al. (2010), Beasley et al. (2011), Harris et al. (2012), and Newcomb et al. (2013) all showed a significant reduction in all-cause or other-cause (excluding breast related) mortality associated with alcohol consumption [44]-[47]. Newcomb et al. (2013) demonstrated a 15% relative reduction in breast cancer-specific mortality in those who were modest drinkers (3 to 6 drinks/week) prior to diagnosis [47].

Wu et al. (2013) in the California BC Survivorship Consortium (CBCSC) pooled data from 6 California based studies including more than 12,000 women with invasive BC. Although not commented on, their results showed that alcohol consumption was associated with a reduction in overall mortality. Alcohol related mortality was not a primary endpoint of the study; it was one of the multitude of variables for which data had been collected in the individual studies. It was also noted that individual studies varied in their method of collection, some documenting alcohol use as a continuous variable, and others as a categorical variable which arguably limits the usefulness of the data in making significant conclusions. It was also not clear if there had been adjustment for Type 1 error [54].

It is well recognised that moderate alcohol intake is associated with lower overall coronary heart disease related mortality in women. The apparent reduced mortality among drinkers in these studies could be due to a reduction in cardiovascular mortality [48].

4.2. Breast Cancer, Alcohol and BC Recurrence

To the authors’ knowledge, there have been only eight studies that have examined the influence of alcohol on BC recurrence (Table 2). Four of the studies found no association between alcohol and recurrence.

Holm et al. (1993) followed 240 patients who had had surgically treated stage I-II non-metastatic BC for 4 years; this study found no association between alcohol intake and BC recurrence [49].

Saxe et al. (1999) followed 149 patients with non-metastatic BC for at least five years and reported that consuming two alcoholic drinks per week was not associated with the risk of BC recurrence [40].

Flatt et al. (2010) studied alcohol consumption in 3088 women treated for invasive BC with a median follow up of 7 years. Their results concluded that light alcohol intake (10 - 299 g/month), regardless of body weight, did not increase the risk of BC recurrence or all-cause mortality in the cohort of middle-aged women previously diagnosed with BC. In fact the study showed an association between alcohol consumption and reduction in all-cause mortality. The authors of the study proposed several confounding factors to explain this. These included amongst others; women with more serious disease were more likely to be minimal drinkers; and women who were more highly educated were less likely to be minimal drinkers [44].

Vrieling et al. (2012) assessed the association of pre-diagnostic alcohol consumption with survival and recurrence in a prospective cohort study in Germany, including 2522 postmenopausal BC patients aged 50 - 74 years.
In a study of 472 women with early stage BC between 1982 and 1984, it was also found that after a c-stage IIIA diagnosed between 1997 and 2000 [30]. Kwan and colleagues reported that by drinking approximately one half of an alcoholic drink (≥6 g/day) after BC diagnosis, the risk of BC was increased. For recurrence, the RR was 1.35 (95% CI: 1.00 to 1.83), and for breast cancer-specific mortality, the RR was 1.51 (95% CI: 1.05 to 2.38). Their results suggest that consuming three to four standard drinks or more per week is associated with a 1.3-fold increased BC recurrence and 1.5-fold increased risk of BC death especially in postmenopausal and overweight/obese women. Given that recurrence can be a difficult end point to achieve with precision for observational studies not performed in clinical settings; this study has the benefit of excellent follow up of BC recurrence. According to the authors, the overweight and obese women in this study were less likely to consume moderate alcohol consumption (>300 mg/month) vs. alcohol <10 g/month.

Recurrence rate (n = 149, 28 events) HR = 1.08 (95% CI: 0.73 to 1.58).

All-cause mortality: (n = 634, 100 events) vs. non-drinkers.

Recurrence rate: drinkers (n = 478, 74 events) vs. non-drinkers (n = 939, 126 events), HR 1.35 (95% CI: 1.00 to 1.83).

All cause mortality: drinkers (n = 478, 64 deaths) vs. non-drinkers (n = 939, 135 deaths) HR 1.19 (95% CI: 0.87 to 1.62).

Moderate alcohol consumption (> 6 g/d) vs. non drinkers.

Recurrence rate: drinkers (n = 478, 74 events) vs. non-drinkers (n = 939, 126 events), HR 1.35 (95% CI: 1.00 to 1.83).

All cause mortality: drinkers (n = 478, 64 deaths) vs. non-drinkers (n = 939, 135 deaths) HR 1.19 (95% CI: 0.87 to 1.62).

Authors concluded that alcohol consumption was non-linearly associated with increased BC-specific mortality (≥12 g vs. <0.5 g/day: (HR) = 1.74, CI: 1.13, 2.67) but found that alcohol consumption was not associated with overall mortality or BC recurrence.

Herbert et al. (1998) reported that the risk of BC recurrence was increased with the consumption of a beer [51]. In a study of 472 women with early stage BC between 1982 and 1984, it was also found that after accounting for disease stage and age, baseline consumption of beer (drinks/day) (RR = 1.58; 95% CI: 0.71 to 1.18). All-cause mortality: (n = 634, 52 deaths) vs. non drinkers (n = 1133, 139 deaths), HR 0.69 (95% CI: 0.49 to 0.97).

Moderate alcohol consumption (>300 mg/month) vs. alcohol <10 g/month.

Recurrence rate (n = 149, 28 events) HR 0.71 (95% CI: 0.32 to 1.57).

All cause mortality: (n = 149, 26 deaths) HR 1.09 (95% CI 0.81 to 1.46).

Alcohol intake >2 units/day vs. <1 unit/day Recurrence rate: HR 1.65 (95% CI: 1.02 to 2.67).

Cumulated alcohol intake >40 drinking years vs. <1 < drinking years ≤ 10; recurrence rate: HR 2.02 (95% CI: 1.06 to 3.85). Results for breast cancer specific mortality were suggestive of a higher risk but not statistically significant.

Table 2. A summary of the studies on alcohol consumption and breast cancer outcome measured as recurrence and all cause mortality.

<table>
<thead>
<tr>
<th>Author</th>
<th>No of cases, tumour stages</th>
<th>Mean follow-up</th>
<th>End points</th>
<th>Menopausal status and/or age</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. L. Kwan et al., 2010</td>
<td>1897, Stages I to IIIa</td>
<td>7</td>
<td>Recurrence rate, all-cause mortality</td>
<td>Pre-/Post-menopausal</td>
<td>Alcohol consumption (&gt; 6 g/d) vs. non drinkers.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RR = 1.75 (95% CI: 1.00 to 1.83).</td>
</tr>
<tr>
<td>J. R. Herbert et al., 1998</td>
<td>472, Stages I to IIIa</td>
<td>9</td>
<td>Recurrence rate and Breast cancer mortality</td>
<td>20 to 80 years</td>
<td>After accounting for disease stage and age, reported baseline consumption of beer (12 oz drinks/d) (HR 1.58; 95% CI: 1.15 to 2.17) increased the risk of recurrence. Breast cancer deaths (HR 2.33; 95% CI: 1.35 to 4.00).</td>
</tr>
<tr>
<td>M. Holm et al., 2013</td>
<td>1052, Stage not specified</td>
<td>Median follow-up 6 years</td>
<td>Recurrence rate and Breast cancer specific mortality</td>
<td>?</td>
<td>Alcohol intake &gt;2 units/day vs. &lt;1 unit/day Recurrence rate: HR 1.65 (95% CI: 1.02 to 2.67). Cumulated alcohol intake &gt;40 drinking years vs. &lt;1 &lt; drinking years ≤ 10; recurrence rate: HR 2.02 (95% CI: 1.06 to 3.85). Results for breast cancer specific mortality were suggestive of a higher risk but not statistically significant.</td>
</tr>
<tr>
<td>G. A. Saxe, 1999</td>
<td>149, Primary breast cancer</td>
<td>5</td>
<td>Recurrence rate, all-cause mortality</td>
<td>Pre-/Post-menopausal</td>
<td>Alcohol Consumption (per 2 drinks/week).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RR = 0.71 (95% CI: 0.49 to 1.06).</td>
</tr>
<tr>
<td>S. W. Flatt et al., 2010</td>
<td>3088, Stages I to IIIa</td>
<td>7.3</td>
<td>Recurrence rate, all-cause mortality</td>
<td>Pre-/Post-menopausal</td>
<td>Alcohol Consumption (per 2 drinks/week).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RR = 0.71 (95% CI: 0.49 to 1.06).</td>
</tr>
<tr>
<td>A. Vrieling et al., 2012</td>
<td>2522, Stages I to IIIa</td>
<td>6</td>
<td>Recurrence rate, all-cause mortality</td>
<td>Post-menopausal, 50 to 74 years</td>
<td>Alcohol consumption ≥12 g/d vs. &lt;0.5 g/d.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RR = 1.08 (95% CI: 0.73 to 1.58).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>All-cause mortality: HR 1.28 (95% CI: 0.90 to 1.81).</td>
</tr>
</tbody>
</table>
alcohol (4.03 median g/day) compared with normal weight women (6.50 g/day). Yet alcohol was still associated with a detrimental effect among heavier women.

Holm et al. (2013) investigated the association between pre-diagnostic alcohol consumption and BC recurrence and breast cancer-specific mortality in 1052 women diagnosed with early BC in a prospective cohort of 29,875 women [52]. They found a significant association between pre-diagnostic alcohol consumption and BC recurrence with a median follow-up of six years after date of diagnosis, both when using baseline measures of alcohol intake (HR, 1.65; 95% CI: 1.02 to 2.67; >2 units/day vs. ≤1 unit/day) and cumulative alcohol intake (HR, 2.02; 95% CI: 1.06 to 3.85; >40 drinking years vs. 0 < drinking years ≤ 10). Results for BC specific mortality were also suggestive of a higher risk, but were not statistically significant.

Most recently, Kwan et al. (2013) investigated the effect of post-diagnosis alcohol consumption on BC recurrence and mortality. They examined data from 3 prospective cohort studies in the After BC Pooling Project (ABCPP) involving >9000 women diagnosed with non-metastatic breast cancer. After a mean follow up of 10.3 years 1646 recurrences and 1543 deaths had occurred. The overall intake of alcohol was not associated with BC recurrence or mortality. However the risk of recurrence varied significantly by menopausal status. Postmenopausal women who regularly consumed alcohol (≥6.0 g/day) had an increased risk of recurrence (HR, 1.19; 95% CI, 1.01 - 1.40) [53].

The above review of literature revealed a heterogenous association between BC outcome, of recurrence or mortality, and alcohol intake. This may be a reflection of variations in study design and experimental protocols of these independently carried out studies. The studies conducted by Kwan et al. (2010, 2013), Herbert et al. (1998), and Holm et al. (2013), showed a positive correlation between alcohol intake and BC recurrence [30][51]-[53]. Conversely the studies conducted by Holm et al. (1993), Saxe et al. (1999), and Flatt et al. (2010) did not find any association between alcohol intake and BC recurrence [40] [44] [49]. These differences may be explained by the variation in sample size and the duration of follow up. The studies conducted by Holm et al. (1993) and Saxe et al. (1999) may lack sufficient power due to their small sample size. Furthermore the former is based on data collected over 20 years ago; making these less relevant to current clinical practice. Other factors which may explain the variation in findings include; data on alcohol consumption was collected retrospectively, survival analyses were not always controlled for grade and stage of cancer, and lack of data on tumour characteristics such as Lymphovascular invasion, lymph node status, prevalence of triple negative and HER II positivity amongst these cohorts [2] [13].

In summary, two of the eight studies detailed above (Holm et al. (1993) and Saxe et al. (1999)), can arguably be excluded from the review due to small sample size and historical data. Furthermore Flatt et al. (2010) identified a number of significant confounding factors in their study, which brings into question the validity of their results, and lastly Vrieling et al. (2012), although not finding any association between alcohol and BC recurrence, did however find a significantly increased risk of BC specific mortality. Thus, given the above, it can be argued that the current weight of evidence is in favour of a positive association between alcohol consumption and BC recurrence.

It is recognised that determining an individual’s alcohol status is more difficult than broadly categorizing each patient as a “drinker” or “non-drinker”, or indeed as set alcohol statuses. Questionnaires based on alcohol consumption will always be subject to potential confounding variation. Whilst studies are dependent on questionnaires that require patients to be forthcoming with their own alcohol intake, they will be liable to error due to the social undesirability of excessive alcohol intake, and also being medically inadvisable [55]. Drinking statuses may indeed change; due to variance, whilst one must also consider the impact that a diagnosis can make on drinking habits. Many of the more recent studies delineate pre- and post-diagnostic alcohol consumption.

5. Future Research

Our literature review has highlighted the gap in the knowledge and evidence regarding the impact of alcohol consumption on BC outcome. Further research should be aimed at collecting data for alcohol consumption before and after the diagnosis of BC to capture the true impact of alcohol on BC outcome.

Future projects could see research into the potential use of biological markers, for example Ki67; a nuclear marker of cell proliferation. Additionally, other studies could look into the effect of genes such as CCNB1, MK167 and MYBL2; which potentially, could play a role in determining BC recurrence.
6. Conclusion

Alcohol consumption increases the risk and can impact on the outcome of BC. Studies consistently demonstrated a dose-response relationship with significant increase in relative risk per 10 g increment in ethanol consumption [2] [6] [10] [11] [13]. Furthermore even light drinking (up to 1 drink/day) was shown to significantly affect BC risk [14] [15]. The link between alcohol consumption and BC recurrence remains inconclusive. Further research is required, which may be aided by the investigation into the role of biological markers and gene recognition.

Conflict of Interest Statement

There are no conflicts of interest to be declared. No financial support was requested or received in the production of this article.

References


http://guidance.nice.org.uk/PH24/Guidance/pdf/English

[56] Alcohol Units. NHS Choices. Last Updated 26 April 2013.
http://www.nhs.uk/Livewell/alcohol/Pages/alcohol-units.aspx